Marcus Muehlbauer, M.D., Ph.D.
Program Director & Assistant Professor
Department:
MD-GASTROENTEROLOGY
Business Phone:
(352) 273-9476
Business Email:
marcus.muehlbauer@medicine.ufl.edu
About Marcus Muehlbauer
Marcus Mühlbauer, M.D., PhD, received his initial clinical and research training at the University of Regensburg, Germany. In 2006, he became interested in researching the role of the microbiome in inflammatory bowel disease; specifically colitis-associated colon cancer. He joined the laboratory of Christian Jobin, PhD, at the University of North Carolina in Chapel Hill (UNC) and graduated from UNC’s gastroenterology fellowship program in 2014 specializing in inflammatory bowel disease (Crohn’s disease and ulcerative colitis). Dr. Mühlbauer joined UF in June 2015 and became the director of the Inflammatory Bowel and Celiac Disease Program in January 2019. He also serves as director of the University of Florida Fecal Microbiota Transplant Program. Dr. Mühlbauer’s primary focus is achieving the highest quality of life for patients suffering from inflammatory bowel disease.
Accomplishments
Exemplary Teacher Award
2019
·
College of Medicine
Board Certifications
-
Internal MedicineAmerican Board of Internal Medicine
Clinical Profile
Specialties
- Medicine
Subspecialties
- Gastroenterology
Areas of Interest
- Crohn disease
- Pseudomembranous colitis
- Ulcerative colitis
Research Profile
Dr. Mühlbauer’s overarching goal is to provide the best care available for patients suffering from inflammatory bowel disease (Crohn’s disease and ulcerative colitis), or IBD. Besides commercially available treatment options, the University of Florida participates in a variety of new and exciting clinical trials our patients can participate in. Dr. Mühlbauer also works very closely with UF’s cutting edge research labs to find a cure for IBD. Patients can support the development of potentially new treatments by allowing us to collect information from them in a clinical setting and provide extremely small tissue samples during their normally scheduled clinical procedures. Dr. Mühlbauer believes improving the education of physicians in training is of the utmost importance. At UF, we take pride in educating the next generation of IBD physicians so that they can provide the best care to patients suffering from Crohn’s disease or ulcerative colitis in the future.
Publications
2017
Locoregional Effects of Microbiota in a Preclinical Model of Colon Carcinogenesis.
Cancer research.
77(10):2620-2632
[DOI] 10.1158/0008-5472.CAN-16-3472.
[PMID] 28416491.
2016
Altered intestinal microbiota-host mitochondria crosstalk in new onset Crohn’s disease.
Nature communications.
7
[DOI] 10.1038/ncomms13419.
[PMID] 27876802.
2015
Inflammasome-independent role of AIM2 in suppressing colon tumorigenesis via DNA-PK and Akt.
Nature medicine.
21(8):906-13
[DOI] 10.1038/nm.3908.
[PMID] 26107252.
2014
Glass Microparticulate Ingestion: An Unusual and Difficult-to-Diagnose Cause of Chronic Abdominal Pain.
ACG case reports journal.
1(3):137-9
[DOI] 10.14309/crj.2014.29.
[PMID] 26157853.
2014
Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer.
Nature communications.
5
[DOI] 10.1038/ncomms5724.
[PMID] 25182170.
2014
The microbiota protects against ischemia/reperfusion-induced intestinal injury through nucleotide-binding oligomerization domain-containing protein 2 (NOD2) signaling.
The American journal of pathology.
184(11):2965-75
[DOI] 10.1016/j.ajpath.2014.07.014.
[PMID] 25204845.
2013
Epithelial cell-specific MyD88 signaling mediates ischemia/reperfusion-induced intestinal injury independent of microbial status.
Inflammatory bowel diseases.
19(13):2857-66
[DOI] 10.1097/01.MIB.0000435445.96933.37.
[PMID] 24141713.
2013
Stochastic changes over time and not founder effects drive cage effects in microbial community assembly in a mouse model.
The ISME journal.
7(11):2116-25
[DOI] 10.1038/ismej.2013.106.
[PMID] 23823492.
2013
VSL#3 probiotic modifies mucosal microbial composition but does not reduce colitis-associated colorectal cancer.
Scientific reports.
3
[DOI] 10.1038/srep02868.
[PMID] 24100376.
2012
A cell permeable peptide inhibitor of NFAT inhibits macrophage cytokine expression and ameliorates experimental colitis.
PloS one.
7(3)
[DOI] 10.1371/journal.pone.0034172.
[PMID] 22479554.
2012
Intestinal inflammation targets cancer-inducing activity of the microbiota.
Science (New York, N.Y.).
338(6103):120-3
[DOI] 10.1126/science.1224820.
[PMID] 22903521.
2011
Microbial colonization induces dynamic temporal and spatial patterns of NF-κB activation in the zebrafish digestive tract.
Gastroenterology.
141(1):197-207
[DOI] 10.1053/j.gastro.2011.03.042.
[PMID] 21439961.
2010
Reduced expression of fibroblast growth factor receptor 2IIIb in hepatocellular carcinoma induces a more aggressive growth.
The American journal of pathology.
176(3):1433-42
[DOI] 10.2353/ajpath.2010.090356.
[PMID] 20093481.
2010
Tumor necrosis factor and interferon-gamma down-regulate Klotho in mice with colitis.
Gastroenterology.
138(4):1384-94, 1394.e1
[DOI] 10.1053/j.gastro.2009.12.002.
[PMID] 20004202.
2009
Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma.
Cancer science.
100(4):646-53
[DOI] 10.1111/j.1349-7006.2009.01087.x.
[PMID] 19175606.
2009
Analysis of monocyte chemotactic protein-1 gene polymorphism in patients with spontaneous bacterial peritonitis.
World journal of gastroenterology.
15(44):5558-62
[PMID] 19938194.
View on:
PubMed
2009
Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility.
PloS one.
4(6)
[DOI] 10.1371/journal.pone.0006026.
[PMID] 19551144.
2009
Tomato lycopene extract prevents lipopolysaccharide-induced NF-kappaB signaling but worsens dextran sulfate sodium-induced colitis in NF-kappaBEGFP mice.
PloS one.
4(2)
[DOI] 10.1371/journal.pone.0004562.
[PMID] 19234608.
2008
Interleukin-8 expression is regulated by histone deacetylases through the nuclear factor-kappaB pathway in breast cancer.
Molecular pharmacology.
74(5):1359-66
[DOI] 10.1124/mol.108.047332.
[PMID] 18669446.
2008
Regulation and functional impact of lipopolysaccharide induced Nod2 gene expression in the murine epididymal epithelial cell line PC1.
Immunology.
124(2):256-64
[DOI] 10.1111/j.1365-2567.2007.02763.x.
[PMID] 18284470.
2008
Role of TLR9 in hepatic stellate cells and experimental liver fibrosis.
Biochemical and biophysical research communications.
376(2):271-6
[DOI] 10.1016/j.bbrc.2008.08.096.
[PMID] 18760996.
2007
Microbial host interactions in IBD: implications for pathogenesis and therapy.
Current gastroenterology reports.
9(6):497-507
[PMID] 18377803.
View on:
PubMed
2006
PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis.
Journal of hepatology.
45(4):520-8
[PMID] 16876901.
View on:
PubMed
2006
Promoter-hypermethylation is causing functional relevant downregulation of methylthioadenosine phosphorylase (MTAP) expression in hepatocellular carcinoma.
Carcinogenesis.
27(1):64-72
[PMID] 16081515.
View on:
PubMed
2006
Repression of cytochrome P450 activity in human hepatocytes in vitro by a novel hepatotrophic factor, augmenter of liver regeneration.
The Journal of pharmacology and experimental therapeutics.
316(2):822-9
[PMID] 16214878.
View on:
PubMed
2005
Characterization of the human zinc finger protein 267 promoter: essential role of nuclear factor Y.
Biochimica et biophysica acta.
1729(1):14-23
[PMID] 15814297.
View on:
PubMed
2005
In situ expression patterns of melanoma inhibitory activity 2 in healthy and diseased livers.
Liver international : official journal of the International Association for the Study of the Liver.
25(2):357-66
[PMID] 15780062.
View on:
PubMed
2005
Lack of association between the functional CX3CR1 polymorphism V249I and hepatocellular carcinoma.
Oncology reports.
13(5):957-63
[PMID] 15809764.
View on:
PubMed
2005
Strong expression of methylthioadenosine phosphorylase (MTAP) in human colon carcinoma cells is regulated by TCF1/[beta]-catenin.
Laboratory investigation; a journal of technical methods and pathology.
85(1):124-36
[PMID] 15492751.
View on:
PubMed
2004
Differential effects of deoxycholic acid and taurodeoxycholic acid on NF-kappa B signal transduction and IL-8 gene expression in colonic epithelial cells.
American journal of physiology. Gastrointestinal and liver physiology.
286(6):G1000-8
[PMID] 14726307.
View on:
PubMed
2003
Polymorphism of monocyte chemoattractant protein 1 in Crohn’s disease.
International journal of colorectal disease.
18(5):401-5
[PMID] 12904997.
View on:
PubMed
1999
Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR.
Clinical cancer research : an official journal of the American Association for Cancer Research.
5(5):1099-105
[PMID] 10353744.
View on:
PubMed
Grants
Jan 2014
– Oct 2019
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects with Moderately to Severely Active Crohns Disease
Role: Principal Investigator
Funding: JANSSEN RESEARCH AND DEVELOPMENT
Oct 2010
– Oct 2019
SECURE: A Non-Interventional Long-term Post-Marketing Registry of Patients Treated with Certolizumab Pegol (Cimzia?) for Crohn's Disease – Protocol: C87075
Role: Principal Investigator
Funding: SCHWARZ BIOSCIENCES INC
Mar 2005
– Feb 2019
IBD Research and Education – UFF Fund #008463
Role: Principal Investigator
Funding: UF FOU
Education
Residency – Gastroenterology
2012
·
UNC Hospitals
Other Program – Gastroenterology
2008
·
UNC Hospitals
Residency – Gastroenterology
2006
·
University of Regensburg
Medical Degree
2001
·
Universitaet Regenburg
Teaching Profile
Courses Taught
2018
MDC7200 Medicine Clerkship
2018
MDC7203 Senior Medicine Clerk
Contact Details
Phones:
- Business:
- (352) 273-9476
Emails:
- Business:
- marcus.muehlbauer@medicine.ufl.edu